Unlike other therapies for CML, allogeneic hematopoietic SCT (HSCT) is a potentially curative treatment. Survival at 20 years post sibling allogeneic HSCT in low-risk groups is 49%. 1 Relapse post transplant is a significant cause of mortality, the majority occurring within 2 years of transplant and the incidence becoming less frequent over time. 1 Presentation in blast crisis (BC) is uncommon but carries a grave prognosis. BC is less responsive to conventional chemotherapy, and survival post HSCT for BC is lower due to higher relapse rates and treatmentrelated mortality. Five year survival is approximately 18%. 1 We present a patient with CML in lymphoid BC at diagnosis. She was successfully treated by matched sibling HSCT but relapsed in lymphoid BC after 20 years.
This 41-year-old Caucasian woman, with a short history of fatigue, bone pains and fever, sought medical attention in August 1985. Blood analysis showed pancytopenia with circulating blasts. BM morphology and cytochemistry suggested lymphoid BC of CML. Further investigations confirmed these blasts to be TdT positive but were negative for non-specific esterase, periodic acid Schiff and Sudan Black staining. Cytogenetic analysis showed a Ph translocation, t(9;22),(q34;q11), in all cells analyzed. She obtained a complete morphologic remission from her initial therapy (CY, doxorubicin, VCR, prednisone and Lasparaginase) and then proceeded to a non-T-cell-depleted allogeneic HSCT from her HLA-identical brother in October 1985. The conditioning regimen used was CY (120 mg/kg), VCR, L-asparaginase and TBI delivered in a single fraction of 500 cGy. GVHD prophylaxis was with CYA and oral prednisone. Day-100 post transplant, BM biopsy confirmed complete morphologic remission, but cytogenetic analysis revealed ongoing mixed chimerism (60% male vs 40% female) and persistent Ph þ cells, still accounting for 40% of remaining host hematopoiesis. Immunosuppression was abruptly withdrawn in April 1986, and transition to full donor chimerism (100% male) with extinction of the Ph þ cell line had occurred by May 1986 as indicated by repeat BM biopsy and cytogenetic analysis. From June 1986 until 2006 she remained well with excellent quality of life. All investigations between 1986 and 1990 suggested continued cytogenetic remission with 100% donor hematopoiesis. After 1990, follow-up was predominantly by her local physician and cytogenetic/molecular studies were not performed; blood counts in 2002 were normal.
Routine assessment before cataract surgery in February 2006 showed thrombocytopenia and leukocytosis with circulating blasts. BM biopsy was consistent with recurrent lymphoblastic leukemia (480% blasts with immunophenotype; CD34 þ , TdT þ , HLA-DR þ , CD19/20 þ , CD13 dim and CD33 dim, but CD117À and MPOÀ). FISH using X/Y chromosome-specific probes indicated loss of donor chimerism (28% male). Cytogenetic analysis showed evidence of clonal evolution. She now carried four distinct cell lines: a female Ph þ cell line with a further balanced translocation, t(10;18) (q25;p11.2), representing 35% of metaphases; a female cell line with a deletion of the whole short arm of the derivative chromosome 9 and a partial deletion of the long arm of the homologous chromosome 9 (breakpoint 9q32) comprising 16% of metaphases; a normal female (host) cell line representing 20% of metaphases and a normal male (donor) cell line comprising 28% of metaphases analyzed. Molecular analysis was consistent with blast phase of CML (b2a2 breakpoint). There was no evidence of extramedullary disease. She received VCR, prednisone and a 600 mg daily dose of imatinib. 3 months later BM biopsy confirmed complete morphological and cytogenetic remission, increased donor chimerism level of 76% and quantitative reverse transcriptase PCR showed a 2.44 log reduction in BCR-ABL transcripts. In September 2006, disease progression was again noted and she switched to dasatinib followed by donor lymphocyte infusion (10 8 CD3 cells/kg) in December 2006. She received further VCR and prednisone in January 2007; none of these interventions were effective and the decision was taken to change to supportive care. She died in May 2007, 21 years and 9 months after her initial presentation.
Late relapse in CML post allogeneic HSCT has been reported earlier. [2] [3] [4] Recent figures suggest that the incidence of relapse between 5 and 15 years post sibling allogeneic HSCT for chronic-phase CML and advanced stage CML is 17 and 12%, respectively. 4 Relapse so long after HSCT suggests the continued presence of a leukemic clone resistant to radio-chemotherapy and GVL effect, which can repopulate through evasion or overpowering of donor lymphocyte-mediated immune mechanisms. Furthermore, BCR-ABL transcripts may be detected by PCR years after HSCT, and in a published cohort, only 15% of patients post HSCT were persistently negative for BCR-ABL transcripts. 5 Blast crisis carries a dismal prognosis. Salvage options are limited, but include donor lymphocyte infusion and tyrosine kinase inhibitors. Although donor lymphocyte infusion response rates are about 70% in chronic phase, they are less successful in advanced CML. 6 Tyrosine kinase inhibitor therapy is capable of inducing remission in patients with molecular or chronic phase relapse. Response to tyrosine kinase inhibitor therapy is not durable in BC 7 probably due to the accumulation of mutations rendering CML cells less dependent on BCR-ABL signaling.
Despite her advanced disease at presentation, she had an excellent response to conventional chemotherapy, proceeded to allogeneic HSCT and experienced a prolonged period of good health until relapse. She had not had prior exposure to TKI therapy, and rapidly obtained both a complete cytogenetic response and a significant reduction in BCR-ABL transcripts with imatinib. Unfortunately, this was short-lived and she rapidly developed refractory disease.
In conclusion, this case is the latest reported relapse of CML post allogeneic HSCT. This and other similar reports emphasize that long-term quantitative BCR-ABL monitoring of all patients with CML post HSCT is warranted.
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